Skip to content
Gene2Rx home

Try

Loading…

Search couldn't load. Check your connection and try again, or use the medication lookup.

No pages match .

The medication lookup checks any medication by name, including ones without their own page.

Get my report
Contains tacrolimusStrong evidence

Is Prograf affected by genetics?

Yes. Its active ingredient has published pharmacogenetic guidance for a gene that varies between people.

Used for: Preventing organ rejection after kidney, liver, heart, and lung transplant

Genes CYP3A5

Prograf (tacrolimus) dosing is affected by the CYP3A5 gene, in an unusual way. Tacrolimus is broken down by two enzymes, CYP3A4 and CYP3A5, and most people of European ancestry make no working CYP3A5 because of a common variant, CYP3A5*3. Standard doses are built around these non-expressers, so the label for them is "poor metabolizer" even though it is the usual case. People who do make CYP3A5 (expressers) clear tacrolimus faster and tend to have low blood levels on a standard dose. Being an expresser is more common in people of African ancestry, about 7 in 10 in CPIC's estimates, than in people of European ancestry, about 1 in 7. CPIC recommends that expressers start at 1.5 to 2 times the usual dose, with blood levels guiding the dose from there as for everyone. Genotype-guided dosing helps reach target levels sooner, but it has not been shown to reduce rejection or kidney toxicity.

What's in Prograf

Tacrolimus Affected by CYP3A5

Tacrolimus has a narrow therapeutic window: too little risks rejection, and too much causes kidney damage and other toxicity. It is broken down by CYP3A4 and, in people who make it, CYP3A5, in the gut wall and liver. The common CYP3A5*3 variant, and the rarer *6 and *7, produce no working enzyme. About 85 percent of people of European ancestry have two non-working copies, compared with about 30 percent of African American people. CPIC's recommendation for expressers (normal or intermediate metabolizers) is a starting dose 1.5 to 2 times the usual one, not above 0.3 mg/kg/day, followed by adjustment to measured trough levels. Starting doses differ by organ and regimen, and transplant teams measure blood levels whatever the genotype. After a liver transplant, the new liver carries the donor's CYP3A5 genes, so CPIC's recommendation applies to liver recipients only when donor and recipient genotypes match.

Read the full tacrolimus genetics guide

Tacrolimus phenotype recommendations

Published guidance from CPIC and FDA on how tacrolimus should be dosed or substituted based on your CYP3A5 phenotype.

PhenotypeWhat it meansRecommendationEvidence
Normal MetabolizerCYP3A5 Your body breaks down tacrolimus faster than most people, which means a standard dose may not reach effective levels. A higher starting dose is recommended to help prevent organ rejection.

CPIC Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments

FDA Measure drug concentrations and adjust the dosage based on trough whole blood tacrolimus concentrations.

Strong
Intermediate MetabolizerCYP3A5 Your body breaks down this drug faster than many people do, so the usual dose may fall short. A higher starting dose and blood tests are advised.

CPIC Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments

FDA Measure drug concentrations and adjust the dosage based on trough whole blood tacrolimus concentrations.

Strong
Poor MetabolizerCYP3A5 Your body processes tacrolimus at a slower rate, which means the standard dose should achieve effective drug levels. The usual starting dose is appropriate for you.

CPIC Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments

FDA Initiate therapy with recommended starting dose.

Strong
IndeterminateCYP3A5 The impact of your genotype on response to this drug is unknown

CPIC + FDA Initiate therapy with recommended starting dose.

Not rated
Not availableCYP3A5 The impact of your genotype on response to this drug is unknown

CPIC + FDA Initiate therapy with recommended starting dose.

Not rated

The gene behind the guidance

CYP3A5 Cytochrome P450 3A5

CYP3A5 contributes to tacrolimus metabolism. People who express functional CYP3A5 can have different dose requirements from nonexpressers. CPIC guidance uses the inferred phenotype alongside therapeutic drug monitoring.

The v4 definitions distinguish allele function and phenotype consistently. The result informs initial treatment; measured tacrolimus concentrations and clinical response remain necessary.

See all drugs affected by CYP3A5

What this means for you

A CYP3A5 result is most useful before a transplant, when the team chooses the starting dose. After that, blood levels guide the dose, and genotype mainly helps explain why someone has trouble reaching target. If your Gene2Rx report shows you are a CYP3A5 expresser (normal or intermediate metabolizer), tell the transplant team. Consumer DNA arrays are not clinical-grade tests, and some do not cover the *6 and *7 variants, which are common in people of African ancestry; a missed non-working variant would make a non-expresser look like an expresser. Where the result would change a starting dose, a clinical CYP3A5 test is reasonable. Never change your tacrolimus dose because of a genetic result: missed or reduced doses can lead to rejection.

FAQ

Why do CYP3A5 expressers need more tacrolimus, not less?

CYP3A5 is one of the enzymes that break tacrolimus down. People who make it clear tacrolimus faster, so a standard dose gives lower blood levels, and CPIC suggests starting them at 1.5 to 2 times the usual dose. This runs opposite to most genes, where the "poor metabolizer" result is the one that needs a change. For CYP3A5, the poor metabolizer result is the common one that standard doses are designed for, and CPIC has noted that the naming can be confusing.

Does race-based dosing matter if we have the genetic test?

A genotype describes the individual, while ancestry only shifts the odds: in CPIC's estimates about 3 in 10 African American people are non-expressers. The Prograf label notes that African-American patients may need higher doses, and CPIC adds that people of African origin have higher dose needs regardless of CYP3A5 genotype, so other factors are also involved. Either way, blood-level monitoring decides the dose.

Are there other transplant drugs where pharmacogenetics matters?

Of the common transplant drugs, CYP3A5 genotype has a CPIC guideline for tacrolimus only. Cyclosporine, which some regimens use instead, is also broken down by CYP3A enzymes, but there is no CPIC or FDA genetic guidance for cyclosporine, mycophenolate or everolimus. Many medicines, such as azole antifungals, diltiazem and verapamil, change tacrolimus levels, often more than genotype does.

Find out how your genetics affect Prograf

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.